HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Tiagabine--own experience in the refractory epilepsy treatment].

Abstract
Tiagabine belongs to a new generation of antiepileptic drugs with a unique mechanism of action. It is well-absorbable from the gastrointestinal tract, has a linear pharmacokinetics, does not affect cognitive function and it interacts poorly with other antiepileptic drugs. Tiagabine is recommended for adults and children past 12 years of age with epilepsy, suffering from partial seizures, with and without secondary generalization. Following the period of a great enthusiasm as to the use of tiagabine, it was put aside, though unfairly, according to the author's own studies as well as the reports in current literature, it still has its place in the treatment of drug-resistant epilepsy.
AuthorsBarbara Błaszczyk
JournalWiadomosci lekarskie (Warsaw, Poland : 1960) (Wiad Lek) Vol. 66 Issue 2 Pt 2 Pg. 175-9 ( 2013) ISSN: 0043-5147 [Print] Poland
Vernacular TitleTiagabina--doświadczenia własne w leczeniu padaczki lekoopornej.
PMID25775813 (Publication Type: Journal Article, Review)
Chemical References
  • Anticonvulsants
  • Neuroprotective Agents
  • Nipecotic Acids
  • Tiagabine
Topics
  • Adult
  • Anticonvulsants (therapeutic use)
  • Child
  • Clinical Trials as Topic
  • Cognition (drug effects)
  • Drug Prescriptions
  • Epilepsy (drug therapy)
  • Humans
  • Neuroprotective Agents (therapeutic use)
  • Nipecotic Acids (therapeutic use)
  • Tiagabine
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: